Literature DB >> 9017086

Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome.

F E Visser1, A P Aldenkamp, A C van Huffelen, M Kuilman, J Overweg, J van Wijk.   

Abstract

Institutionalized patients with Down syndrome (n = 307) were monitored for 5 to 10 years prospectively to determine prevalence of Alzheimer-type dementia. Clinical signs, cognitive functioning, and EEGs were assessed. When possible, postmortem neuropathological examinations were conducted. Progressive mental and physical deterioration was found for 56 of the residents. Mean age at onset of dementia was 56 years. Prevalence increased from 11% between ages 40 and 49 to 77% between 60 and 69. All patients 70 and over had dementia. Neuropathological findings were consistent with clinical diagnosis. Use of a dementia checklist, cognitive skills inventory, and EEG reliably detected Alzheimer-type dementia at an early stage.

Entities:  

Mesh:

Year:  1997        PMID: 9017086

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  39 in total

1.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

2.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

3.  Does ceruloplasmin differential express in the brain of Ts65Dn: a mouse mode of Down syndrome?

Authors:  Bin Yu; Jing Kong; Baoling Xing; Ziqiang Zhu; Bin Zhang; Qiu-Wei Wang; Shi-He Shao
Journal:  Neurol Sci       Date:  2013-11-17       Impact factor: 3.307

4.  Cognitive impairment and EEG background activity in adults with Down's syndrome: a topographic study.

Authors:  Svetla Velikova; Giuseppe Magnani; Claudia Arcari; Monica Falautano; Massimo Franceschi; Giancarlo Comi; Letizia Leocani
Journal:  Hum Brain Mapp       Date:  2011-05       Impact factor: 5.038

Review 5.  Neuropsychiatric and behavioral aspects of trisomy 21.

Authors:  Jeannie Visootsak; Stephanie Sherman
Journal:  Curr Psychiatry Rep       Date:  2007-04       Impact factor: 5.285

6.  Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

Authors:  M Nistor; M Don; M Parekh; F Sarsoza; M Goodus; G E Lopez; C Kawas; J Leverenz; E Doran; I T Lott; M Hill; E Head
Journal:  Neurobiol Aging       Date:  2006-08-09       Impact factor: 4.673

7.  Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

Authors:  Eleonore Bayen; Katherine L Possin; Yingjia Chen; Laurent Cleret de Langavant; Kristine Yaffe
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

8.  Upregulation of SET expression by BACE1 and its implications in Down syndrome.

Authors:  Xiaozhu Zhang; Yili Wu; Xiaoling Duan; Wei Chen; Haiyan Zou; Mingming Zhang; Shuting Zhang; Fang Cai; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

9.  Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

Authors:  Fabio Di Domenico; Raffaella Coccia; Annalisa Cocciolo; M Paul Murphy; Giovanna Cenini; Elizabeth Head; D Allan Butterfield; Alessandra Giorgi; Maria Eugenia Schinina; Cesare Mancuso; Chiara Cini; Marzia Perluigi
Journal:  Biochim Biophys Acta       Date:  2013-04-18

10.  Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.

Authors:  Benjamin L Handen; Ann D Cohen; Umapathy Channamalappa; Peter Bulova; Sheila A Cannon; William I Cohen; Chester A Mathis; Julie C Price; William E Klunk
Journal:  Alzheimers Dement       Date:  2012-11       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.